AU1002

AU1002 is an early-stage investigational medication developed by Aurospharma for appetite regulation and weight management in patients with obesity and metabolic disorders. The drug is designed to modulate appetite-regulating centers in the brain to reduce constant hunger without the use of stimulants, needles, or addictive substances. Positioned as an affordable and non-invasive alternative to current obesity treatments, AU1002 aims to help patients maintain a healthy diet and increased physical activity by resetting hunger signals. It is currently in the early stages of development as a needle-free (likely oral) therapeutic option.